139 related articles for article (PubMed ID: 11438818)
21. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
22. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
23. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
24. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
25. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
26. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
[TBL] [Abstract][Full Text] [Related]
27. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
[TBL] [Abstract][Full Text] [Related]
30. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
31. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
Lenhoff S; Hjorth M; Turesson I; Westin J; Gimsing P; Wislöff F; Ahlberg L; Carlson K; Christiansen I; Dahl IM; Forsberg K; Brinch L; Hammerström J; Johnsen HE; Knudsen LM; Linder O; Mellqvist UH; Nesthus I; Nielsen JL;
Haematologica; 2006 Sep; 91(9):1228-33. PubMed ID: 16956822
[TBL] [Abstract][Full Text] [Related]
32. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
33. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J
J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704
[TBL] [Abstract][Full Text] [Related]
34. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution.
Bladé J; Esteve J; Rives S; Martínez C; Rovira M; Urbano-Ispizua A; Marín P; Carreras E; Montserrat E
Bone Marrow Transplant; 2000 Oct; 26(8):845-9. PubMed ID: 11081383
[TBL] [Abstract][Full Text] [Related]
35. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
38. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
39. Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.
Patriarca F; Sperotto A; Filì C; Zaja F; Prosdocimo S; Fanin R
Haematologica; 2002 Jul; 87(7):779-81. PubMed ID: 12091134
[TBL] [Abstract][Full Text] [Related]
40. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
